Beauty Health Company
SKIN Micro CapConsumer Defensive · Household & Personal Products
Mis à jour: Jun 18, 2026, 22:21 UTC
Price Chart
Indicateurs clés
Valuation Analysis
About the Company
Beauty Health Company en bref
Beauty Health Company (SKIN) is currently trading at 0,58 € with a market capitalization of 75 M €. The 52-week range spans from 0,48 € to 2,35 €; the current price is 75.5% below the yearly high. Year-over-year revenue growth stands at -6.7%.
💰 Dividende
Beauty Health Company currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.
📊 Avis des analystes
6 analystes évaluent Beauty Health Company (SKIN) au consensus : None. L'objectif de cours moyen est de 1,17 €, soit un potentiel de +102.42% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 0,87 € à 1,74 €.
Beauty Health Company : la thèse d'investissement en détail
Beauty Health Company (SKIN) operates in the Consumer Defensive — specifically Household & Personal Products — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.
Le scénario haussier
With a gross margin near 64.91%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns.
Le scénario baissier
Revenue is contracting at -6.7% year-over-year — until that trend reverses, valuation is exposed to further downgrades. Net margins remain negative, meaning every euro of revenue is still producing losses — the path to profitability is the central question for shareholders. The debt-to-equity ratio of 664.61% is elevated, meaning the company relies heavily on creditors — refinancing terms will become more important than operational performance in the next economic downturn.
Valorisation en contexte
With a PEG ratio of 0.93, the price-to-earnings multiple is actually below the company's growth rate — classic value-meets-growth territory that Peter Lynch would have called a 'GARP' opportunity.
À surveiller
- The price sits in the lower quartile of the 52-week range — value hunters often start scaling in around this zone if fundamentals hold.
- The analyst consensus price target implies 102.42% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.
Thèse d'investissement : forces et faiblesses
- Marge brute élevée de 64.91% — signe d'un pouvoir de fixation des prix
- Free cash flow positif
- –CA en contraction (-6.7% sur un an)
- –Actuellement non rentable
- –Endettement élevé (D/E 664.61)
- –Positions vendeuses élevées (30.12%)
Aperçu technique
Price is below both the 50- and 200-day moving averages, with 50d below 200d — a bearish picture (death-cross alignment).
Profil de risque
The data points to market-like volatility, elevated short interest (30.12%), higher leverage relative to equity.
Trading Data
Related Stocks in the Same Sector
More Consommation de Base stocks
Top peers in the same sector — ranked by market cap.
Where can I buy Beauty Health Company?
Compare top-rated brokers — low fees, trusted providers, fully regulated.
Live Market Data
Real-time chart, financials, earnings, analysts, insider trades, events & news